Zhenghui (Alan) Wang Ph.D.

Alan Wang is a partner in the firm’s Technology and Life Sciences groups.

Dr. Wang represents pharmaceutical, biotechnology, diagnostic and medical device companies in domestic and cross-border complex life sciences and technology transactions, including co-development, licensing and collaboration, manufacturing, supply and distribution, M&A and other intellectual property transactions.

• Represented Multitude Therapeutics in its license agreement with Adcendo ApS for the development of a first-in-class ADC targeting Tissue Factor, with up to $1 billion in upfront and milestone payments
  
• Represented MabCare Therapeutics in its exclusive license agreement with Day One Biopharmaceuticals for development and commercialization of MabCare’s solid tumor ADC with $55 million upfront and up to $1.15 billion in potential milestone payments
  
• Advised Marina Oncology in its acquisition by Novartis for $1 billion upfront and $750 in potential milestone payments
  
• Represented Arvinas in its additional milestones license agreement with Novartis Pharma for development and commercialization of PROTAC, androgen receptor degrader for patients with prostate cancer, with $150 million upfront and up to $1.01 billion in potential milestone payments
• Represented Oak Hill Bio in a license and development agreement with Chiesi Group to develop, manufacture and commercialize OHB-607, a recombinant version of insulin-like growth factor-1 (IGF-1) product
• Represented Teva Pharmaceuticals in a collaboration with Sanofi to co-develop and co-commercialize Teva’s anti-TL1A antibody product, with $500 million upfront payment and up to $1 billion in development and launch milestones payments
• Represented Orionis Biosciences in a collaboration with Genetech to discover and develop molecular glue class medicines, with an upfront $47 million payment and a potential of more than $2 billion development, commercial and sales milestone payments
• Represented Multitude Therapeutics in a licensing collaboration with OnCusp Therapeutics for the development and commercialization of a potentially highly differentiated second-in-class CDH6 antibody drug conjugate
• Represented Karuna Therapeutics in a strategic collaboration with Zai lab for development, manufacturing, and commercialization of KarXT in Greater China, with $35 million upfront payment and up to $80 million in development and regulatory milestones and $72 million in sales milestones payments
• Advised Arvinas in its global collaboration agreement with Pfizer to develop and commercialize ARV-471 with $650 million upfront payment and $350 million equity investment in Arvinas from Pfizer, and a potential $1.4 billion in milestone payments
• Advised Codiak Biosciences in its sale of its exosome manufacturing facility and related assets to Lonza, with Codiak receiving approximately $65 million of in-kind manufacturing services for its clinical-stage programs and retaining core exosome engineering and loading expertise, and Lonza gaining access to the worldwide exclusive rights of Codiak’s high-throughput exosome manufacturing technology
• Represented Prime Medicine in their option and research collaboration with Myeloid Therapeutics to develop and accelerate next-generation RNA-based Gene-Editing Technology, RetroT™, with $45 million upfront payment from Prime
• A leading biotechnology company in collaboration with a multinational pharmaceutical company to develop, manufacture and distribute advanced antibody products for the treatment and prevention of COVID-19*
• A multinational pharmaceutical company in collaboration with a U.S. biotechnology company for potential therapeutics and vaccines against COVID-19*
• A multinational pharmaceutical company in a global license and collaboration arrangement with a clinical-stage public biotech company in China for anticancer inhibitor products*
• A UK pharmaceutical company in the divestiture of its rights related to a prescription opioid medicine in China* 
• A South Korean e-commerce company, in a sale of its Japanese business platform to a U.S. multinational e-commerce corporation*

*Denotes experience prior to joining Goodwin.

Prior to joining Goodwin, Dr. Wang was at another leading international law firm, where he focused on representing multinational pharmaceutical companies and biotechnology companies in various life sciences and technology transactions. Dr. Wang also has extensive experience in China-related cross-border licensing and collaboration, as well as supply and distribution transactions.

While attending law school, Dr. Wang served as the Editor for the Cornell Law Review. 

Dr. Alan Wang has been recognized by The Best Lawyers in America Ones to Watch for his work in Intellectual Property Law 2022.